Stem Cell Culture Patents: Who Leads, Where the Gaps Are 2026
- Filing peaked in 2021 at 20 records, then fell sharply the tracked span shows 20 filings in 2021 dropping to 1 by 2024, a -95% swing that predates the usual 18-month publication lag.
- The top 5 assignees already hold 51.0% of the field 125 of 245 records sit with five organisations, with the leader alone on 44 — a narrow band of institutions and one specialist biotech set most of the claim boundaries.
- Bioreactor apparatus claims trail biology claims by a wide margin C12M (bioreactors & enzyme apparatus) appears in 34.7% of records versus 94.3% for C12N — the hardware side of perfusion control is comparatively open.
Filing growth compares 2021 (20 records) with 2024 (1) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 245 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent families combining stem, pluripotent or progenitor cell culture with perfusion-control concepts — perfusion rate, bleed control, residence time, nutrient renewal, waste removal and steady-state operation — filed or published between 2015 and mid-2026 and classified under C12N5/074, C12N5/0735 or C12M3/00. It captures both the biological side of keeping a stem cell population viable under continuous flow and the apparatus side of the bioreactors that deliver that flow.
Because publication trails filing by roughly 18 months, the most recent one to two years in any trend understate real filing activity — read the 2024 figures as the last complete signal, not the years after it.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
245 published records sit in scope, spread across 73 ranked assignees and eight IPC subclasses that a single record can straddle at once.
Filing rose to a 2021 peak, then fell
Filings climbed to a peak of 20 in 2021 before declining to 1 by 2024, a -95% drop over that three-year span. Because publication lags filing by around 18 months, 2025 and 2026 figures are still filling in and should not be read as confirmation the field has cooled — only 2021-2024 is a safe comparison window.
Biology claims dominate; apparatus claims lag
C12N (microorganisms & genetic engineering) touches 94.3% of the 245 records, with A61K (medicinal preparations) at 44.1% and C12M (bioreactors & apparatus) at 34.7%. The gap between C12N and C12M is the clearest signal in the composition: culture biology is claimed far more densely than the hardware that runs it.
Shares are the percentage of the 245 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Stem Cell Culture Perfusion Culture with Eureka
This page is one run against one query. Ask Eureka your own question about stem cell culture perfusion culture and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited prior art and a representative filing
US20080085557A1 — Human Cancer Stem Cell Culture Compositions Comprising Erbb2 Variants and Methods of Use Thereof
The present invention provides compositions and methods for the culture and maintenance of cancer stem cells. More particularly, the present invention provides the identification of cancer stem cell specific markers and methods of recognizing the same for the detection of tumors, for facilitating the prognosis of a patient with a tumor, and for the treatment of various cancers. The invention also provides antibodies that specifically recognize the disulfide linked Erbb2Δ16 homodimer, an Erbb2Δ16/Erbb3 heterodimer, or post-translational modifications of Erbb2 that are specific to Erbb2 of variant hESCs, together with a modified defined media useful in their absence.Filed by ViaCyte, Inc., published 2008-04-10.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6043066A | Cell separation using electric fields | 298 |
| 2 | WO2010124290A2 | Compositions and methods for deriving or culturing pluripotent cells | 221 |
| 3 | US5399493A | Methods for human gene therapy, including methods and compositions for the ex vivo replication and stable gen… | 185 |
| 4 | US5686289A | Method and compositions of a bioartificial kidney suitable for use in vivo or ex vivo | 183 |
| 5 | US5728581A | Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein | 178 |
| 6 | US5670351A | Methods and compositions for the ex vivo replication of human hematopoietic stem cells | 169 |
| 7 | US5549674A | Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo | 140 |
| 8 | WO2005007799A2 | Methods for ex-VIVO expanding stem/progenitor cells | 115 |
| 9 | WO1992011355A1 | Method for culturing and transforming human stem cell-containing compositions | 105 |
| 10 | US20060205071A1 | Methods for ex-vivo expanding stem/progenitor cells | 102 |
Citation counts reward older filings that have had longer to accumulate references — treat this as a signal of influence within the corpus, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns stand out once the raw counts are put in context: where the field is claimed, how concentrated ownership is, and how citation weight is distributed.
Ownership sits with a narrow band of institutions
The top 5 assignees combine for 125 of 245 records (51.0%), and the top 10 reach 66.5% (163 records). The leader alone accounts for 44 records, well ahead of fifth place at 12 — a steep drop-off rather than a gradual one.
Peak filing has passed, on the complete-year data
Filings rose to a peak of 20 in 2021 and fell to 1 by 2024. That drop is real within the complete-year window, though the 2025-2026 counts are still filling in under the usual publication lag and should not be read as a continuation of the same slope.
Apparatus claims trail biology claims by a wide margin
C12N-classed biology claims appear in 94.3% of records versus 34.7% for C12M-classed bioreactor and apparatus claims. Sterilising and disinfecting art (A61L) sits lowest at 5.7%, suggesting the physical hardware and process-control layers of perfusion culture carry less claim density than the cell biology itself.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to stem cell culture perfusion culture, with the prior art for and against each one.
Who is filing, and where the field is still open
A handful of academic medical centres and one perfusion-focused biotech set the pace; beyond the top 10 the field thins into single- and double-filing entrants.
One assignee filed nearly a fifth of the field alone
The leading assignee holds 44 of 245 records, more than three times fifth place at 12. That gap suggests one organisation staked out core claim territory early rather than the field converging on a shared standard.
A tight mid-tier before the long tail begins
Positions five through ten narrow from 12 records down to 5, then the ranking spreads across 73 assignees in total — most of them holding only one or two records each.
Collaboration is limited and concentrated
Only 10 co-assignee pairs appear across the dataset, and the strongest pairings recur around the same specialist biotech and its named inventors — collaboration here looks more like internal inventor-assignee links than cross-company joint filing.
| Assignee | Recent year | YoY |
|---|---|---|
| The General Hospital Corporation | 0 | — |
| The Regents of the University of Michigan | 0 | — |
| ViaCyte, Inc. | 0 | — |
| Cellular Dynamics International, Inc. | 0 | — |
| INSCEPTION BIOSCI | 0 | — |
| Agency for Science, Technology and Research (A*STAR) | 0 | — |
| FUJIFILM Cellular Dynamics, Inc. | 0 | — |
| The Governing Council of the University of Toronto | 0 | — |
Where to take this next
The counts here describe what has been filed and published; turning that into a filing or freedom-to-operate decision needs a closer read of specific claims.
Check freedom-to-operate against the leader's claim set
With one assignee holding 44 of 245 records, any new filing in this space should start by mapping its claims against that portfolio before drafting.
Run a claim comparison in EurekaTest the apparatus white space
C12M apparatus claims sit at 34.7% of records against 94.3% for core biology claims — a lower-density area worth probing for open claim scope.
Explore white space in EurekaWatch the 2025-2026 publication window
Because publication lags filing by about 18 months, filings made in late 2024 and 2025 are still arriving in the record — worth re-checking this landscape once that window closes.
Set a monitoring alert in EurekaCommon questions on this landscape
One assignee leads with 44 of the 245 records in scope, well ahead of the field. The top 5 assignees combine for 51.0% of all records and the top 10 reach 66.5%, so ownership is concentrated in a narrow band of academic medical centres and one perfusion-focused biotech rather than spread evenly across the 73 ranked assignees. Anyone entering this space should expect to negotiate around or design around that leading portfolio first.
Filings peaked at 20 in 2021 and had fallen to 1 by 2024, a -95% change across that complete-year window. Because patent publication lags filing by roughly 18 months, the 2025 and 2026 figures in any dataset are still incomplete and should not be read as proof the field has kept declining. The safest read is that filing activity cooled markedly after 2021 based on the years that are fully counted.
C12N, covering microorganisms and genetic engineering techniques, appears in 94.3% of the 245 records in scope, making it the densest single class. A61K (medicinal preparations) follows at 44.1% and C12M (bioreactors and apparatus) at 34.7%, with sterilising and disinfecting art (A61L) the thinnest at 5.7%. A record can carry more than one class, so these figures overlap rather than sum to 100%.
The clearest gap sits between biology claims and apparatus claims: C12N-classed biology appears in 94.3% of records while C12M-classed bioreactor and apparatus claims cover only 34.7%. Sub-areas like automated bleed-rate control, steady-state nutrient sensing hardware and closed-system waste removal look under-claimed relative to the biological composition claims layered on top of them. That gap is a reasonable starting point for a first claim focused on the physical control layer rather than the cell biology itself.
US20080085557A1, assigned to ViaCyte, Inc. and published 2008-04-10, claims compositions and methods for culturing and maintaining cancer stem cells, including specific markers, antibodies recognising Erbb2 variant forms, and a modified defined culture media. It is one representative filing in this dataset rather than the most-cited one, and its scope is narrower than the field-wide perfusion-control claims — it does not block general bleed-control or residence-time methods on its own. Anyone relying on it for freedom-to-operate should read its granted claims directly rather than the published-application abstract.
Research Stem Cell Culture Perfusion Culture in depth with Eureka
Go past this page: query the whole stem cell culture perfusion culture corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.